库欣病患者诊断前及长期随访中的精神药物使用:一项全国性研究
该全国性纵向注册研究纳入1990至2018年瑞典垂体注册中诊断为库欣病(CD)的372例患者及匹配对照,分析诊断前5年至长期随访期间精神药物配药情况。结果显示,CD患者在诊断前及诊断时抗抑郁药、抗焦虑药和安眠药使用均较对照更常见,且随访5年时抗抑郁药和安眠药使用仍升高;持续缓解亚组中抗抑郁药和安眠药使用亦较高,提示心理健康负面影响持续存在。
要点
- CD患者诊断前5年及诊断时抗抑郁药、抗焦虑药和安眠药使用显著高于对照。
- 随访5年时抗抑郁药和安眠药使用仍升高,而降压药和降糖药使用下降。
- 持续缓解患者抗抑郁药和安眠药使用仍较高,提示需长期监测心理健康。
核心结论
- 库欣病患者在诊断前及长期随访中精神药物使用增加,且不因缓解状态而完全逆转,提示对心理健康有持续负面影响。
研究设计与样本
- 全国性纵向注册研究,纳入1990至2018年瑞典垂体注册中诊断的372例库欣病患者,每例匹配4名对照,并收集诊断前5年、诊断时及随访期间数据。
- 对76例持续缓解患者进行横断面亚组分析。
主要发现
- 诊断前5年及诊断时,CD患者抗抑郁药使用OR分别为2.2(95%CI 1.3-3.7)和2.3(1.6-3.5),抗焦虑药为2.9(1.6-5.3)和3.9(2.3-6.6),安眠药为2.1(1.2-3.7)和3.8(2.4-5.9),均高于对照。
- 随访5年时,抗抑郁药OR为2.4(1.5-3.9),安眠药OR为3.1(1.9-5.3),仍升高。
- 诊断时和随访5年时,CD患者抗抑郁药使用比例(26%)和安眠药使用比例(22%)不变,而降压药和降糖药使用减少。
- 持续缓解中位9.3年(IQR 8.1-10.4)的患者,抗抑郁药OR为2.0(1.1-3.8),安眠药OR为2.4(1.3-4.7),降压药无升高。
临床怎么用
- 对库欣病患者应关注诊断前及长期随访中的精神心理问题,并监测精神药物使用。
- 即使达到持续缓解,仍需长期关注抗抑郁药和安眠药使用情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Psychiatric symptoms are common in Cushing's disease (CD) and seem only partly reversible following treatment. OBJECTIVE: To investigate drug dispenses associated to psychiatric morbidity in CD patients before treatment and during long-term follow-up. DESIGN: Nationwide longitudinal register-based study. SETTING: University Hospitals in Sweden. SUBJECTS: CD patients diagnosed between 1990 and 2018 (N = 372) were identified in the Swedish Pituitary Register. Longitudinal data was collected from 5 years before, at diagnosis, and during follow-up. Four matched controls per patient were included. Cross-sectional subgroup analysis of 76 patients in sustained remission was also performed. MAIN OUTCOME MEASURES: Data from the Swedish Prescribed Drug Register and the Patient Register. RESULTS: In the 5-year period before and at diagnosis, use of antidepressants (odds ratio [OR] 2.2 [95% confidence interval (CI) 1.3-3.7]) and 2.3 [1.6-3.5]), anxiolytics [2.9 (1.6-5.3) and 3.9 (2.3-6.6)], and sleeping pills [2.1 (1.2-3.7) and 3.8 (2.4-5.9)] was more common in CD than controls. ORs remained elevated at 5-year follow-up for antidepressants [2.4 (1.5-3.9)] and sleeping pills [3.1 (1.9-5.3)]. Proportions of CD patients using antidepressants (26%) and sleeping pills (22%) were unchanged at diagnosis and 5-year follow-up, whereas drugs for hypertension and diabetes decreased. Patients in sustained remission for median 9.3 years (interquartile range 8.1-10.4) had higher use of antidepressants [OR 2.0 (1.1-3.8)] and sleeping pills [2.4 (1.3-4.7)], but not of drugs for hypertension. CONCLUSIONS: Increased use of psychotropic drugs in CD was observed before diagnosis and remained elevated regardless of remission status, suggesting persisting negative effects on mental health. The study highlights the importance of early diagnosis of CD, and the need for long-term monitoring of mental health.
引用
- Bengtsson D, Ragnarsson O, Berinder K, et al. Psychotropic Drugs in Patients with Cushing's Disease Before Diagnosis and at Long-Term Follow-Up: A Nationwide Study. J Clin Endocrinol Metab. 2021. PMID: 33567076. doi:10.1210/clinem/dgab079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。